Clinical Trials Logo

Hyponatremia clinical trials

View clinical trials related to Hyponatremia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06020495 Not yet recruiting - Hyponatremia Clinical Trials

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia: a Multicenter Open-label Randomized Controlled Trial

DASSOH
Start date: January 1, 2024
Phase: Phase 3
Study type: Interventional

ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.

NCT ID: NCT05408481 Not yet recruiting - COVID-19 Clinical Trials

Relation Between COVID-19 Pts and Hyponatremia in Adreno Ortical Insufficient Patients.

Start date: June 2022
Phase:
Study type: Observational

Hyponatremia in COVID-19 patients with adrenal insufficiency

NCT ID: NCT03941405 Not yet recruiting - Cirrhosis, Liver Clinical Trials

Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)

AlbuCAT
Start date: July 2020
Phase: Phase 2
Study type: Interventional

resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period

NCT ID: NCT02709031 Not yet recruiting - Diabetes Clinical Trials

Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium

CHAMP
Start date: June 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes. It is evident from in vitro, animal and human studies that cicletanine's optimal dose in diabetes and other challenging, critically-unmet needs is likely to be higher than that for hypertension. Cicletanine's maximum tolerated dosage is not known, but the drug's dose-limiting effects are documented to be potassium loss and sodium loss from thiazide-type activity (one of the therapeutic mechanisms the drug is known to have); such thiazide-type losses are known to be reversed safely by magnesium. This trial explores the ability of magnesium to enhance cicletanine safety at higher doses in a trial involving patients with hypertension complicated by diabetes.

NCT ID: NCT02399358 Not yet recruiting - Hyponatremia Clinical Trials

Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide

Start date: December 2015
Phase: N/A
Study type: Observational

Prospoctive cohort of high-dose cyclophosphamide exposed patients. With active estandardize screening of hyponatremia development in the follow up period.

NCT ID: NCT01716611 Not yet recruiting - Hyponatremia Clinical Trials

Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites

TONIC
Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate the efficacy and safety for the management of hyponatremia and ascites in patients with liver cirrhosis.

NCT ID: NCT01509170 Not yet recruiting - Hyponatremia Clinical Trials

The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia

0597-10-HMO
Start date: February 2012
Phase: N/A
Study type: Observational

The aim of this study is to identify factors associated with hyponatremia among patients hospitalized in the internal medicine ward. Consequtive patients hospitalized because of hyponatremia will be recruited. Follow up will include clinical factors such as background diseases, complete drug history, blood tests including Biochemistry tests (Sodium, renal function), endocrinological evaluation, thyroid function tests, cortisol,urinary sodium on addmition. One month following discharge follow up Sodium level will be taken.

NCT ID: NCT01425606 Not yet recruiting - Clinical trials for Hyponatremia of Multiple Myeloma

Pseudohyponatremia of Multiple Myeloma is True Hyponatremia

Start date: September 2011
Phase: Phase 4
Study type: Observational

Hypothesis: the hyponatremia of multiple myeloma (m.m.)is true and not pseudohyponatremia by using the stewart approach to acid - base interpretation, would like to show that the positive charged m- proteins produced in m.m.result in true hyponatremia.